<span item_type="fundamental" item_id="12eb91caa051fc58981dda9713ede351" counter_id="ST/US/IVP" env="prod"></span><span item_type="announcement" item_id="516463854838875393" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 3.639 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.43.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -2.415 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Service Revenue</strong>: $2,741,029 for the three months ended March 31, 2025, compared to $3,545,599 for the same period in 2024, representing a decrease of 23%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li><li><strong>Product Revenue</strong>: $898,180 for the three months ended March 31, 2025, compared to $1,285,968 for the same period in 2024, representing a decrease of 30%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $2,415,036 for the three months ended March 31, 2025, compared to $3,421,792 for the same period in 2024, representing a decrease in net loss by 29%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li><li><strong>Total Operating Expenses</strong>: $5,646,517 for the three months ended March 31, 2025, compared to $7,694,072 for the same period in 2024, representing a decrease of 27%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: $1,374,297 for the three months ended March 31, 2025, compared to $3,169,029 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $2,528,915 for the three months ended March 31, 2025, compared to $3,216,090 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Adjusted Clinics EBITDA</strong>: $5,146 for the three months ended March 31, 2025, compared to $16,735 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue expanding its acquisition of veterinary hospitals, with a focus on general practice, specialty hospitals, and emergency care services. The strategy includes acquiring multi-unit practices to facilitate growth and enhance market presence.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring opportunities in mixed animal care, including equine and bovine care, as part of its long-term growth strategy.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1939365/000121390025044156/ea0241890-10q_inspire.htm"></span></li></ul>

Inspire Veterinary Partners | 10-Q: FY2025 Q1 Revenue: USD 3.639 M